The downfall of that company was in its actions by going off label and other unscrupulous promotional activities. That is not the case here.
The case against Acadia is a shorter supposedly making a case for the overpriced Acadia share price and basing a lot of its assertions on Daybue being less than successful with follow thru repeats.
I am sure Acadia will be looking hard at the numbers and the reasons (if there are any) and making appropriate strategic decisions. After all it has paid good upfront money for the worldwide rights!
As someone has previously pointed out Neuren is collateral damage. This would only be of monetary success to Culper if they had a short position in NEU. Is there any evidence of that Culper has such a position? None of which has been disclosed by them in their report. Maybe the authorities or NEU could request such disclosure from Culper?
Ann: Comment on research report, page-169
-
- There are more pages in this discussion • 148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $18.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.65 | 1127 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |